戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tonin transporter; and SLC18A2, encoding the vesicular monoamine transporter.
2 calized within the nerve varicosities by the vesicular monoamine transporter.
3 nd in vivo binding of these compounds to the vesicular monoamine transporter.
4 n vitro and in vivo for binding to the brain vesicular monoamine transporter.
5 hinese hamster ovary cells expressing either vesicular monoamine transporter.
6 his exon leads to increased activity of both vesicular monoamine transporters.
7 mine neurons because of the apparent lack of vesicular monoamine transporters.
8 Our results demonstrate that the presynaptic vesicular monoamine transporter 1 (VMAT1) Thr136Ile (rs1
9                                         Both vesicular monoamine transporter 1 and 2 contain several
10 gic terminals, using a ligand for the type 2 vesicular monoamine transporter, (+)-[11C]dihydrotetrabe
11 mine transporter, serotonin transporter, and vesicular monoamine transporter 2 (like cocaine and meth
12 In this study, we used mice heterozygous for vesicular monoamine transporter 2 (VMAT2 +/- mice) to de
13 ity of mice lacking the neuronal form of the vesicular monoamine transporter 2 (VMAT2) affords the op
14                     TH1-S31E associated with vesicular monoamine transporter 2 (VMAT2) and alpha-synu
15 affinity dopamine transporter (DAT), and the vesicular monoamine transporter 2 (VMAT2) as assessed 2-
16                                              Vesicular monoamine transporter 2 (VMAT2) catalyzes tran
17                      Because the location of vesicular monoamine transporter 2 (VMAT2) defines the se
18 genic mouse with a hypomorphic allele of the vesicular monoamine transporter 2 (Vmat2) gene by gene t
19 y monoamines, we have disrupted the neuronal vesicular monoamine transporter 2 (VMAT2) gene.
20                                          The vesicular monoamine transporter 2 (VMAT2) has sequence h
21            Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor appr
22 ements over the past decade in understanding vesicular monoamine transporter 2 (VMAT2) inhibitors hig
23                                          The vesicular monoamine transporter 2 (VMAT2) is a proton-de
24                                              Vesicular monoamine transporter 2 (VMAT2) is an essentia
25 -cell mass (BCM) in the pancreas showed that vesicular monoamine transporter 2 (VMAT2) is highly expr
26                                          The vesicular monoamine transporter 2 (VMAT2) is localized p
27              We previously reported that the vesicular monoamine transporter 2 (VMAT2) is physically
28 lase (TH) neurons projecting to the LHb lack vesicular monoamine transporter 2 (VMAT2) mRNA, and ther
29 ng the transcriptional activation of the rat vesicular monoamine transporter 2 (VMAT2) promoter in ga
30 droxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein.
31    We produced a conditional deletion of the vesicular monoamine transporter 2 (VMAT2) specifically i
32 scent false neurotransmitter 200 (FFN200), a vesicular monoamine transporter 2 (VMAT2) substrate that
33 rough the coordinated activity of astroglial vesicular monoamine transporter 2 (VMAT2) together with
34                                              Vesicular monoamine transporter 2 (VMAT2) transports mon
35 levels of the dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) were increased
36 ogaine inhibit the transport function of the vesicular monoamine transporter 2 (VMAT2) with submicrom
37 (BB) diabetic rats, using antibodies against vesicular monoamine transporter 2 (VMAT2), a marker of s
38 d Pb-exposed mice were immunostained for the vesicular monoamine transporter 2 (VMAT2), serotonin (5-
39 bination to generate mutant mice lacking the vesicular monoamine transporter 2 (VMAT2), the predomina
40  produce norepinephrine (NE) and contain the vesicular monoamine transporter 2 (VMAT2), which package
41 s by viral vector-mediated overexpression of vesicular monoamine transporter 2 (VMAT2).
42 th tracers for the serotonin transporter and vesicular monoamine transporter 2 (VMAT2).
43 ontained both vesicular transporters for DA [vesicular monoamine transporter 2 (VMAT2)] and GABA [ves
44                                          The vesicular monoamine transporter 2 (VMAT2, SLC18A2) takes
45                                          The vesicular monoamine transporter 2 (VMAT2; SLC18A2) is re
46 omosome (BAC)-mediated overexpression of the vesicular monoamine transporter 2 (VMAT2; Slc18a2).
47 tion by a mutation in SLC18A2 (which encodes vesicular monoamine transporter 2 [VMAT2]).
48 e varicosities in the outer retina possessed vesicular monoamine transporter 2 and vesicular GABA tra
49 ly smaller than the dopamine transporter and vesicular monoamine transporter 2 defects, suggesting up
50 ing high-fidelity imaging of pHluorin-tagged vesicular monoamine transporter 2 in dopamine neurons, w
51              Deutetrabenazine is a selective vesicular monoamine transporter 2 inhibitor approved for
52                        Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor approved in
53 ine (NBI-98854) is a novel, highly selective vesicular monoamine transporter 2 inhibitor that demonst
54                                              Vesicular monoamine transporter 2 is important for the a
55                          SLC18A2 encodes the vesicular monoamine transporter 2 protein that regulates
56            TH(+) cells expressed both VMAT2 (vesicular monoamine transporter 2) and VGAT (vesicular G
57 gold electron microscopy detection of VMAT2 (vesicular monoamine transporter 2) establish the presenc
58  odds ratio (OR)=1.4, p=2.1E-05) in SLC18A2 (vesicular monoamine transporter 2).
59 emission tomography (PET) radioligand to the vesicular monoamine transporter 2, (VMAT2), [(11)C]dihyd
60 e, which includes tyrosine hydroxylase (TH), vesicular monoamine transporter 2, and the norepinephrin
61 on-enriched genes tyrosine hydroxylase (TH), vesicular monoamine transporter 2, dopamine transporter
62 ne toxicity, YY1 increases expression of the vesicular monoamine transporter 2, vMAT2, while coordina
63               Here, we demonstrated that the vesicular monoamine transporter 2-dependent dopamine upt
64  with the PET ligands, indicating that these vesicular monoamine transporter 2-directed ligands did n
65 ither vesicular acetylcholine transporter or vesicular monoamine transporter 2.
66 [2,1-a]isoquinolin-2-ol ((18)F-AV-300)} bind vesicular monoamine transporter 2.
67  tyrosine hydroxylase, the DA transporter or vesicular monoamine transporter 2.
68                            In the brain, the vesicular monoamine transporter-2 (VMAT(2)) is responsib
69 ofiles of tyrosine hydroxylase (TH), DAT and vesicular monoamine transporter-2 (VMAT) in the striatum
70 s vesicular [3H]DA uptake and binding of the vesicular monoamine transporter-2 (VMAT-2) ligand dihydr
71                                              Vesicular monoamine transporter-2 (VMAT-2) plays a criti
72 ydrotetrabenazine (DTBZ) binding site on the vesicular monoamine transporter-2 (VMAT2) and their abil
73 ctivity was abolished in the presence of the vesicular monoamine transporter-2 (VMAT2) inhibitor rese
74 nd equatorial geometry, respectively, of the vesicular monoamine transporter-2 (VMAT2) inhibitor, lob
75 roscopic immunocytochemistry to localize the vesicular monoamine transporter-2 (VMAT2), a novel marke
76 ot accumulated into synaptic vesicles by the vesicular monoamine transporter-2 (VMAT2).
77 n of an efficient relay between SERT and the vesicular monoamine transporter-2 (VMAT2).
78 dent on the concerted action of AMPH on both vesicular monoamine transporter-2 and DAT.
79                         Furthermore, DAT and vesicular monoamine transporter-2 expressions were simil
80 y of fixed doses of deutetrabenazine-a novel vesicular monoamine transporter-2 inhibitor-in patients
81  acid decarboxylase, the DA transporter, and vesicular monoamine transporter-2 with EGFP in midbrain
82 of DAT with cocaine and by inhibition of the vesicular monoamine transporter-2 with Ro-4-1284 or rese
83 s regulating dopamine synthesis and release: vesicular monoamine transporter-2, tyrosine hydroxylase,
84 ABA, the GABA vesicular transporter, and the vesicular monoamine transporter-2.
85  synaptic vesicles by specific transporters (vesicular monoamine transporter-2; VMAT2) using energy f
86                               Binding to the vesicular monoamine transporter, a measure of total dopa
87 tron emission tomography imaging of striatal vesicular monoamine transporters and 11C-Pittsburgh comp
88 d (2) display reduced off-target activity at vesicular monoamine transporters and 5-HT(2B)-receptors,
89 tron emission tomography imaging of striatal vesicular monoamine transporters and cerebrocortical dep
90                                              Vesicular monoamine transporters are known to transport
91 ivatives displayed in vitro affinity for the vesicular monoamine transporter binding site in rat brai
92                                          The vesicular monoamine transporter can protect against toxi
93 Ms, and packed into synaptic vesicles by the vesicular monoamine transporter, CAT-1, expressed in the
94 n vivo, we used a mutation in the Drosophila vesicular monoamine transporter (dVMAT) as a sensitized
95 erminal trafficking domain of the Drosophila vesicular monoamine transporter (DVMAT), which is requir
96 ve characterized mutations in the Drosophila vesicular monoamine transporter (dVMAT), which is requir
97 wn that mice with a 95% genetic reduction in vesicular monoamine transporter expression (VMAT2-defici
98                A second isoform of the human vesicular monoamine transporter (hVMAT) has been cloned
99 ter (hVAChT) and the neuronal isoform of the vesicular monoamine transporter (hVMAT2) are differentia
100  the large intraluminal loop of the neuronal vesicular monoamine transporter (hVMAT2-loop) as probes
101                              CGRP-, SP-, and vesicular monoamine transporter-immunostained neurites a
102 benazine is a high-affinity inhibitor of the vesicular monoamine transporter in mammalian brain.
103 ansporter, and the presence of both types of vesicular monoamine transporters in the exocrine cells o
104                                 Reserpine, a vesicular monoamine transporter inhibitor, had no effect
105 ents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine
106                                   Effects of vesicular monoamine transporter inhibitors on catecholam
107  PHEN and D2-PHEN was assessed by inhibiting vesicular monoamine transporter-mediated storage into ve
108                                              Vesicular monoamine transporters package monoamine neuro
109 ntration of a stable presynaptic marker, the vesicular monoamine transporter protein (VMAT2), was qua
110 haracterized bacterial homologues of the rat vesicular monoamine transporter (rVMAT2).
111                         Molecular cloning of vesicular monoamine transporters shows sequence similari
112 , its metabolites, and the expression of the vesicular monoamine transporter, suggesting a decrease i
113 ce P (SP) (sensory C and A delta fibers) and vesicular monoamine transporter (sympathetic fibers).
114  immunostaining for VMAT2, an isoform of the vesicular monoamine transporter that loads catecholamine
115 te that when quantal size is altered via the vesicular monoamine transporter the concentration of cat
116 n which DA is efficiently channeled from the vesicular monoamine transporter to membranous DbetaM for
117 l regulation of decarboxylase activity (FD), vesicular monoamine transporter type 2 (DTBZ), and dopam
118                                              Vesicular monoamine transporter type 2 (VMAT2) imaging w
119 rabenazine ([(11)C]DTBZ) binding to striatal vesicular monoamine transporter type 2 (VMAT2) in cocain
120                                          The vesicular monoamine transporter type 2 (VMAT2) is coexpr
121 e whether sequestration by the intracellular vesicular monoamine transporter type 2 (VMAT2) occurs, m
122                                          The vesicular monoamine transporter type 2 (VMAT2) packages
123 NBI-750142, an experimental inhibitor of the vesicular monoamine transporter type 2 (VMAT2) was obtai
124                                          The vesicular monoamine transporter type 2 (VMAT2), an impor
125 emistry showed that D(3) dopamine receptors, vesicular monoamine transporter type 2 (VMAT2), and dopa
126  ((18)F-DTBZ), a novel radiotracer targeting vesicular monoamine transporter type 2 (VMAT2), has been
127 eurons, autoradiographic measures of DAT and vesicular monoamine transporter type 2 (VMAT2), striatal
128                           In particular, the vesicular monoamine transporter type 2 (VMAT2), which is
129                                              Vesicular monoamine transporter type 2 and benzodiazepin
130                                              Vesicular monoamine transporter type 2 and benzodiazepin
131 ET images demonstrated that the reduction of vesicular monoamine transporter type 2 availability was
132                       The mean reductions of vesicular monoamine transporter type 2 density for the c
133                                     Striatal vesicular monoamine transporter type 2 expression in dem
134 erase and [(11)C]dihydrotetrabenazine (DTBZ) vesicular monoamine transporter type 2 positron emission
135 ic resonance and [(11)C]dihydrotetrabenazine vesicular monoamine transporter type 2 positron emission
136 was confirmed by [(11)C]dihydrotetrabenazine vesicular monoamine transporter type 2 positron emission
137 [(11) C]dihydrotetrabenazine (DTBZ; reflects vesicular monoamine transporter type 2), ex vivo quantif
138  future in vivo measurements of the striatal vesicular monoamine transporter type 2.
139 icles by one of two proton-amine exchangers, vesicular monoamine transporters type 1 and 2 (VMAT1 and
140  postmortem studies have shown low levels of vesicular monoamine transporter, type 2 (VMAT2), the mem
141 that acute pharmacological inhibition of the vesicular monoamine transporter (VMAT) blocks amphetamin
142  have exploited the broad requirement of the vesicular monoamine transporter (VMAT) for the vesicular
143                             Packaging by the vesicular monoamine transporter (VMAT) is essential for
144                        Overexpression of the vesicular monoamine transporter (VMAT) rescued the dopam
145 responsive FFNs) as novel probes that act as vesicular monoamine transporter (VMAT) substrates and ra
146 rs for the bovine adrenal chromaffin granule vesicular monoamine transporter (VMAT) that have been pr
147 reserpine, a small-molecule inhibitor of the vesicular monoamine transporter (VMAT) that repackages m
148 icular acetylcholine transporter (VAChT) and vesicular monoamine transporter (VMAT) transport neurotr
149                                              Vesicular monoamine transporter (VMAT), a member of the
150 ore, parachloroamphetamine (pCA), acting via vesicular monoamine transporter (VMAT), and a charged VM
151 ing pharmacological blockers of SERT and the vesicular monoamine transporter (VMAT), we have identifi
152                                              Vesicular monoamine transporter (VMAT)-2 has a crucial r
153 lase (TH), dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT).
154  is one of the best known substrates for the vesicular monoamine transporter (VMAT).
155 d independently of synaptic targeting of the vesicular monoamine transporter (VMAT).
156 inimum by continuous pumping activity of the vesicular monoamine transporter (VMAT)2.
157 sion of norepinephrine transporter (NET) and vesicular monoamine transporter (VMAT-1) was evaluated i
158                         Antisera against the vesicular monoamine transporters VMAT1 and VMAT2 demonst
159 sferase (COMT), monoamine oxidase-A (MAO-A), vesicular monoamine transporter (VMAT1,2) and chromogran
160 sfection to increase expression of the brain vesicular monoamine transporter VMAT2 and presynaptic am
161 amate in vitro and in vivo, we have used the vesicular monoamine transporter VMAT2 and the vesicular
162 -electron microscopy structures of the human vesicular monoamine transporter VMAT2 in complex with th
163 icles (LDCVs) depends on localization of the vesicular monoamine transporter VMAT2 to LDCVs.
164 promote axonal dopamine release by targeting vesicular monoamine transporter VMAT2 to the axon rather
165 stead, GABA release requires activity of the vesicular monoamine transporter VMAT2, which is the vesi
166 choline transporter (VAChT) and the neuronal vesicular monoamine transporter (VMAT2) as important mol
167 ne D1-like and D2-like receptors, and type 2 vesicular monoamine transporter (VMAT2) binding sites we
168  and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function.
169          The subcellular localization of the vesicular monoamine transporter (Vmat2) mRNA corresponds
170 The hypothesis that human cocaine users lose vesicular monoamine transporter (VMAT2) protein was test
171                                    The brain vesicular monoamine transporter (VMAT2) pumps monoamine
172  To identify residues in the neuron-specific vesicular monoamine transporter (VMAT2) responsible for
173  the regional cerebral density of the type 2 vesicular monoamine transporter (VMAT2) using positron e
174                                          The vesicular monoamine transporter (VMAT2) was absent befor
175 Confocal microscopy analysis showed that the vesicular monoamine transporter (VMAT2) was decreased in
176 ransporter (DAT) and increased levels of the vesicular monoamine transporter (VMAT2) were detected in
177 atory polymorphisms in the brain form of the vesicular monoamine transporter (VMAT2) which affect its
178                                       Type 2 vesicular monoamine transporter (VMAT2), found in the br
179 e knowledge of the Slc18a2 gene encoding the vesicular monoamine transporter (VMAT2), involved in the
180 rotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (VMAT2), with positron e
181 tanserin and TBZ are both antagonists of the vesicular monoamine transporter (VMAT2).
182                                       Type 2 vesicular monoamine transporters (VMAT2) are expressed i
183                      The two closely related vesicular monoamine transporters (VMATs) 1 and 2 differ
184                                          The vesicular monoamine transporters (VMATs) 1 and 2 show cl
185 ons(1-5)-are stored in secretory vesicles by vesicular monoamine transporters (VMATs) for controlled
186 rong sequence similarity, and studies of the vesicular monoamine transporters (VMATs) indicate prefer
187 esicles (SLMVs), whereas the closely related vesicular monoamine transporters (VMATs) localize prefer
188                                              Vesicular monoamine transporters (VMATs) pack monoamines
189                                          The vesicular monoamine transporters (VMATs) package monoami
190                                              Vesicular monoamine transporters (VMATs) translocate mon
191         Molecular cloning has identified two vesicular monoamine transporters (VMATs), one expressed
192 norhabditis elegans homolog of the mammalian vesicular monoamine transporters (VMATs); it is 47% iden
193 rotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter, with positron emission

 
Page Top